In a public letter Pfizer (PFE) CEO Albert Bourla wrote that the company hopes to have initial data from its Phase 3 clinical trail of a coronavirus vaccine by the end of October and that it will wait until the third week in November to file an emergency use authorization application with the U.S. Food […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
